CompletedNot Applicable

Evaluation of Inflammatory Markers in LARC Patients

245 participantsStarted 2010-01-01

Plain-language summary

Introduction: In locally advanced rectal cancers (LARC), TNM staging is far from optimal. We aimed to investigate the value of previously described circulating biomarkers as predictors of prognosis. Methods: Retrospective analysis of 245 LARC patients diagnosed between January 2010 and December 2022, who underwent neoadjuvant chemoradiotherapy and surgery at two centers. A Cox regression and Kaplan-Meier analysis were performed.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients diagnosed pathologically with rectal adenocarcinomas, located within 12cm from the anal verge (measured by MRI), clinically staged T3-4 and/or N+ and treated with neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery Exclusion Criteria: * evidence of distant metastasis at diagnosis, emergent or palliative surgery, local excision or "watch and wait" approach and evidence of inflammatory or hematological disorders

What they're measuring

Overall survival Disease-free survival

Timeframe: 5 years

Trial details

NCT IDNCT05893667

SponsorHospital Pedro Hispano

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-01

View on ClinicalTrials.gov More Locally Advanced Rectal Cancer trials